<DOC>
	<DOCNO>NCT02244606</DOCNO>
	<brief_summary>The purpose study compare safety , pharmacokinetics , efficacy oral SCY-078 vs. standard-of-care follow initial intravenous echinocandin therapy treatment invasive candidiasis .</brief_summary>
	<brief_title>Oral SCY-078 v Standard-of-Care Following IV Echinocandin Treatment Invasive Candidiasis</brief_title>
	<detailed_description>Patients receive initial intravenous ( IV ) echinocandin therapy . Patients eligible randomization receive SCY-078 500-mg orally , SCY-078 750-mg orally , standard-of-care .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Diagnosis invasive candidiasis define positive culture blood another normally sterile site Candida . Not reproductive potential reproductive potential , agree remain abstinent use 2 method contraception . Patient Candida endocarditis , osteomyelitis , meningitis , chronic disseminate candidiasis evidence endophthalmitis . Patient fail treatment echinocandin episode invasive candidiasis . Infection limit oropharynx , esophagus , urogenital system , skin , sputum/bronchoalveolar lavage culture . Participation clinical study investigational drug ( ) within 30 day prior study entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Invasive Candidiasis</keyword>
	<keyword>Invasive Candida infection</keyword>
	<keyword>Candidemia</keyword>
	<keyword>SCY-078</keyword>
	<keyword>Micafungin</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Echinocandin</keyword>
</DOC>